Genetically modified dendritic cells in cancer therapy: Implications for transfusion medicine

Transfusion Medicine Reviews

Volumn 15, Issue 4, 2001, Pages 292-304

  Foley, Ronan ^a,b,c   Tozer, Richard ^a,b   Wan, Yonghong ^a,b  

^a HAMILTON HEALTH SCIENCES   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c HAMILTON REGIONAL LABORATORY MEDICINE PROGRAM   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CD34 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE; CYTOKINE; FLT3 LIGAND; GENTAMICIN; GLYCOPROTEIN GP 100; GLYCOPROTEIN GP 39; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 4; INTERLEUKIN 6; PENICILLIN DERIVATIVE; PROSTAGLANDIN E2; RECOMBINANT INTERLEUKIN 2; STREPTOMYCIN; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ADENOVIRUS; ANIMAL MODEL; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER THERAPY; CELL CULTURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENDRITIC CELL; GENE TRANSFER; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; MELANOMA; MONOCYTE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROTEIN EXPRESSION; REVIEW; SPLEEN CELL; T LYMPHOCYTE; TUMOR IMMUNOLOGY; VACCINATION;

EID: 0034800201     PISSN: 08877963     EISSN: None     Source Type: Journal    
DOI: 10.1053/tm.2001.26960     Document Type: Review

References (67)

1. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma
2. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome
3. High dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma
4. Dendritic cells: Unique leukocyte populations which control the primary immune response
5. The dendritic cell system and its role in immunogenicity
6. Isolation and function of human dendritic cells
7. Immunobiology of dendritic cells
8. Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy
9. Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells in the bone marrow and peripheral blood
10. Delineation of the dendritic cell lineage by generating large numbers of birbeck granule- positive Langerhans cells from human peripheral blood progenitor cells in vitro
11. Dendritic cells: Development, function and potential use for cancer immunotherapy
12. Adoptive immunotherapy of cancer using monocyte-derived macrophages: Rationale, current status, and perspectives
13. Dendritic cells transduced with an adenoviral vector encoding a model tumorassociated antigen for tumor vaccination
14. Murine dendritic cells transduced with an adenoviral vector expressing a defined tumor antigen can overcome anti-adenovirus neutralizing immunity and induce effective tumor regression
15. Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells
16. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity
17. Dendritic cell vaccines for cancer immunotherapy
18. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides
19. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
20. Gp 100/pmel 17 is a murine tumor rejection antigen: Induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand
21. Human dendritic cells, pulsed with either melanoma tumor cell lysates or the gp 100 peptide (280-288), induce pairs of T-cell cultures with similar phenotype and lytic activity
22. Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage
23. Tumour-specific MHC-class-II-restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and Annexin II eluted from melanoma cells
24. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
25. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity
26. Cell adhesion in the immune system
27. Interactions between immunogenic peptides and MHC proteins
28. Cell biology of antigen processing and presentation to major histocompatibility complex class 1 molecule-restricted T lymphocytes
29. Antigen recognition by class I - Restricted T lymphocytes
30. The B7 and CD28 receptor families
31. TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties
32. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: Application to autoimmune disease therapy
33. Linking innate and adaptive immunity
34. Dendritic cells but not macrophages are targets for immune regulation by natural killer cells
35. Cross-linking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells
36. CD4 T cell cytokine differentiation: The B-cell activation molecule, OX40 ligand, instructs CD4 T cells to express interleukin 4 and upregulates expression of the chemokine receptor, Blr-1
37. Costimulation of CD28-T T lymphocytes by 4-1BB ligand
38. A, CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand
39. Dendritic cells enhance growth and differentiation of CD40- activated B lymphocytes
40. Human dendritic cells skew isotype switching of CD40- activated naïve B cells towards IgA 1 and IgA2
41. A role for endogenous transforming growth factor beta 1 in Langerhans cell biology: The skin of transforming growth factor beta 1 null mice is devoid of epidermal Langerhans cells
42. Functional and morphological characterization of 4F7+ spleen accessory dendritic cells
43. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application
44. A method for the production of cryopreserved aliquots of antigen-preloaded, mature dendritic cells ready for clinical use
45. Gene-modified dendritic cells for use in tumor vaccines
46. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected denderitic cells
47. Human dendritic cells transfected with RNA encoding prostate- specific antigen stimulate prostate-specific CTL response in vitro
48. Induction of primary carcinoembryonic antigen (CEA)- specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA
49. Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines
50. Methods for construction of adenovirus vectors
51. The use of adenoviral vectors for gene therapy and gene transfer in vivo
52. A controlled study of adenoviral- vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis
53. Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs
54. Dendritic cells transduced with an adenovirus vector encoding Epstein-Barr virus latent membrane protein 2B: A new modality for vaccination
55. Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector
56. Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells
57. Murine dendritic cells infected with adenovirus vectors show signs of activation
58. Adenovrial transduction of human "clinical grade' immature dendritic cells enhances costimulatory molecule expression and T-cell stimulatory capacity
59. Adenoviral vectors targeted to CD40 enhances the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model
60. Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas
61. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity
62. GP Report from the International Union Against Cancer (UICC) Tumor Biology Committee: UICC workshop on the use of dendritic cells in cancer clinical trials
63. Dendritic cell immunotherapy of metastatic melanoma using CD34+ hematopoietic progenitor-derived cells (CD34-DC) induced immune responsed to melanoma antigen and resulted in clinical regression of metastatic disease
64. Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatment
65. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - Long term results of a clinical trial
66. Homing of intravenously and intralymphatically injected human dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells